Neuromuscular disorders: molecular and therapeutic insights

Lancet Neurol. 2005 Jan;4(1):6-7. doi: 10.1016/S1474-4422(04)00946-9.
No abstract available

Publication types

  • Review

MeSH terms

  • Campylobacter jejuni / isolation & purification
  • Distal Myopathies / drug therapy
  • Distal Myopathies / metabolism
  • Drug Therapy, Combination
  • G(M1) Ganglioside / metabolism
  • Guillain-Barre Syndrome / drug therapy
  • Guillain-Barre Syndrome / metabolism
  • Guillain-Barre Syndrome / microbiology
  • HLA-DR3 Antigen / genetics
  • Haplotypes
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Lipopolysaccharides / metabolism
  • Methylprednisolone / therapeutic use
  • Mutation
  • Myositis, Inclusion Body / drug therapy
  • Myositis, Inclusion Body / metabolism
  • Neuromuscular Diseases / drug therapy*
  • Neuromuscular Diseases / genetics
  • Neuromuscular Diseases / immunology
  • Neuromuscular Diseases / metabolism*
  • Neuromuscular Diseases / microbiology
  • Randomized Controlled Trials as Topic

Substances

  • HLA-DR3 Antigen
  • Immunoglobulins, Intravenous
  • Lipopolysaccharides
  • G(M1) Ganglioside
  • Methylprednisolone